Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find studies

Showing 26–50 of 79 studies in Prevention trials of type randomised controlled trial (page 2 of 4) · 30,980 in the whole library · How the 0–100 score works

Download bibliography of these 79 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

What “Prevention trials” covers

Prevention trials — Trials that test whether a specific diet, lifestyle change or supplement actually slows cognitive decline.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

The FINGER MRI exploratory sub-study did not show significant differences between the intervention and control groups on changes in regional brain volumes, regional cortical thicknesses, or WML volume after 2 years in at-risk elderly without substantial impairment. 5 key findings →

Design: randomized controlled trial Participants: 132 Evidence: high

Exercise for Individuals with Lewy Body Dementia: A Systematic Review

✓ Peer-reviewed alzhub usefulness score 77 out of 100. PloS one 2016-06-03

111,485 articles were initially retrieved; 288 full articles were reviewed and 89.6% subsequently deemed ineligible due to exclusion of participants with co-existence of dementia and Parkinsonism. 5 key findings →

Design: randomized controlled trial Participants: 16 Evidence: high

Alzheimer's dementia (AD) is the sixth leading cause of death in the U.S., with an estimated $305 billion cost of care in 2020. 1 key finding →

Design: randomized controlled trial Participants: 604 Evidence: high

A 2-year lifestyle intervention was able to maintain the daily functioning of the at-risk older population. 3 key findings →

Design: randomized controlled trial Participants: 1,260 Evidence: high

CCT proved effective in PD-MCI patients when compared with traditional PCT. 4 key findings →

Design: randomized controlled trial Participants: 53 Evidence: high

Combined multi-domain interventions may contribute to preventing or delaying disease progression. 1 key finding →

Design: randomized controlled trial Participants: 33 Evidence: high

The 2-year multidomain FINGER intervention may modulate white matter microstructural alterations. 2 key findings →

Design: randomized controlled trial Participants: 34 Evidence: high

Systematic cognitive training had no effect on global cognition or HRQoL in community-living persons with mild to moderate dementia. 1 key finding →

Design: randomized controlled trial Participants: 147 Evidence: high

In a large dementia prevention trial with 6-year follow-up, dropout was associated with older age, poorer cognitive function, symptoms of depression, and disability at baseline. 4 key findings →

Design: randomized controlled trial Participants: 2,994 Evidence: high

Relative to HC, the participants with cTBI had lower CAC (0.10 ± 0.03 vs 0.12 ± 0.03 mm 2 /mm Hg, P = .046) and higher CVR (0.17 ± 0.03 vs 0.15 ± 0.03 mm Hg/mL/min, P = .028). 4 key findings →

Design: randomized controlled trial Evidence: high

Outcomes from this trial support the conduct of a larger and longer trial with this participant group. 4 key findings →

Design: randomized controlled trial Participants: 57 Evidence: high

If results from this study show benefits for cognition at trial completion, CCT programs, alone or in combination with walking, might be a strategy to promote healthy cognitive aging in older adults. 3 key findings →

Design: randomized controlled trial Evidence: high

In this pilot study, RFM and the multi-domain approach CPR were feasible and had preliminary beneficial effects in older adults with MCI in primary care setting in Hong Kong. 3 key findings →

Design: randomized controlled trial Evidence: high

Cognitive training involving speed of cognitive processing has the potential to delay the diagnosis of ADRD. 1 key finding →

Design: randomized controlled trial Participants: 2,021 Evidence: high

Cognitive training in Parkinson's disease reduces cognitive decline in the long term

✓ Peer-reviewed alzhub usefulness score 72 out of 100. European journal of neurology 2014-12-22

This study gives evidence that cognitive training may be effective to prevent cognitive decline and onset of MCI in PD patients. 3 key findings →

Design: randomized controlled trial Evidence: high

Aerobic exercise combined with computerized cognitive training has better effects on the cognitive functional status of survivors of stroke than an active control. 1 key finding →

Design: randomized controlled trial Participants: 30 Evidence: high

A 26-wk group-based exercise program combined with dual-task training improved GCF in community-dwelling older adults without dementia. 3 key findings →

Design: randomized controlled trial Participants: 44 Evidence: high

One-year repeated cycles of cognitive training (CT) for Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 72 out of 100. Aging clinical and experimental research 2013-06-20

Present results suggest that repeated cycles of CT in patients with AD treated with ChEIs are associated with benefits in several areas of cognitive function. 3 key findings →

Design: randomized controlled trial Participants: 16 Evidence: high

This is the first randomized controlled trial with supervised moderate-to-high intensity exercise in patients with mild AD. 4 key findings →

Design: randomized controlled trial Participants: 200 Evidence: high

They provide initial evidence that cognitive training may be an efficacious approach toward improving balance and gait in older adults known to have a history of falls. 3 key findings →

Design: randomized controlled trial Participants: 45 Evidence: high

However, to replace existing nonpharmaceutical treatment training protocols, VR platforms need significant improvement if they are to appeal to older people with symptoms of cognitive decline and meet their specific needs. 3 key findings →

Design: randomized controlled trial Evidence: high

This trial that enlist the support of private enterprises will lead to the creation of new services for dementia prevention as well as to verify the effectiveness of multi-domain interventions for dementia prevention. 5 key findings →

Design: randomized controlled trial Evidence: high

Despite differences in CVR management within the countries considered, it was possible to design and implement the HATICE multidomain intervention. 4 key findings →

Design: randomized controlled trial Evidence: high

Intradialytic Cognitive and Exercise Training May Preserve Cognitive Function

✓ Peer-reviewed alzhub usefulness score 69 out of 100. Kidney international reports 2017-08-19

Preliminary findings of our pilot study suggested that cognitive decline in psychomotor speed and executive function is possibly prevented by intradialytic CT and ET. 4 key findings →

Design: randomized controlled trial Evidence: high

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events